Jennifer C. Smith-Parker spoke with Sergey Jakimov and Artem Trotsyuk in a Denatured podcast episode released on Mar. 26 about the importance of focusing on specific targets in drug development to address age-related diseases.
The discussion highlights the growing interest in longevity investing, particularly the need for concrete strategies rather than general ideas when developing drugs aimed at increasing lifespan.
Smith-Parker, who is Director of Insights at BioSpace, hosted Jakimov, managing partner at LongeVC, and Trotsyuk, operating partner for LongeVC in the United States. The conversation centered on how efforts to extend human life should prioritize addressing distinct age-related illnesses through precise scientific methods.
Jakimov and Trotsyuk discussed their perspectives as investors and operators within the longevity sector. They emphasized that successful progress depends on identifying clear biological targets related to aging rather than relying solely on broad concepts or buzzwords.
The guests clarified that their views are personal and do not represent those of their organizations. The episode is available for listening on several platforms including Spotify, Apple Podcasts, Amazon Music, and iHeart.
